Basiliximab

Basiliximab is a special medicine used to help prevent organ rejection after a kidney transplant. It's a type of antibody that blocks a specific protein on immune cells called T-lymphocytes. This helps stop your body from attacking the new kidney.

Brand names:Simulect
Medication

What people taking Basiliximab report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Basiliximab

What It's For

Basiliximab, sold as Simulect, is a medicine given around the time of a kidney transplant to lower the chance that the immune system attacks the new kidney in the first weeks after surgery. This early attack is called acute rejection, and it is most likely soon after a transplant. Basiliximab is an induction treatment: a short, intensive course of immune suppression given at the start, alongside the anti-rejection medicines a person will keep taking afterward, such as cyclosporine or tacrolimus and corticosteroids (steroid medicines like prednisone). It does not replace those long-term medicines. In the US it is approved only for kidney transplants, in adults and children. Some transplant centers use it for other organs, but the label notes that its benefit there has not been shown.

How It Works

Basiliximab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is part of the receptor for interleukin-2 (IL-2), a signaling molecule that T cells, a type of white blood cell, use to multiply once they have been switched on. When T cells recognize a transplanted kidney as foreign, IL-2 signaling helps them expand into a large attacking force. By blocking that receptor, basiliximab keeps activated T cells from responding to the IL-2 growth signal, which blunts the rejection response while the body adjusts to the new organ. Because the receptor appears mainly on T cells that are already activated, the drug acts on a narrow part of the immune system. Two doses keep the receptor blocked for roughly a month or more, covering the period when rejection risk is highest.

Dosage & Administration

Basiliximab is given only in a hospital or transplant center, by clinicians experienced in transplant immune suppression. It goes into a vein (intravenously), either as an infusion over 20 to 30 minutes or as a quicker injection. The usual course is two doses. The first is given within 2 hours before transplant surgery, and the second 4 days after the transplant, usually while the person is still in the hospital. Adults and children weighing 35 kg (about 77 pounds) or more receive 20 mg per dose; smaller children receive 10 mg. The second dose may be skipped if a serious allergic reaction occurs or the new kidney is lost. There is nothing to take at home: the ongoing anti-rejection pills are a separate part of the plan.

Side Effects

In the large trials, people who received basiliximab had about the same side effects as people who received a placebo (an inactive dummy treatment). Constipation, nausea, stomach pain, swelling in the legs, high blood pressure, headache, tremor, trouble sleeping and changes in blood potassium or sugar were common in both groups. These mostly reflect transplant surgery and the other anti-rejection medicines rather than basiliximab itself. A faster injection can cause nausea, vomiting or pain where it is given. The main serious risk is a severe allergic reaction, including anaphylaxis, which can happen with the first dose or when the drug is given again months or years later. Signs include hives, itching, wheezing, trouble breathing or swallowing, a racing heartbeat and feeling faint. Because doses are given in the hospital, tell the nurse right away if any of these start; the team keeps treatment for these reactions on hand, and a severe reaction means basiliximab is stopped for good. Rare reactions involving fluid leaking from blood vessels, causing rapid swelling and weight gain, have also been reported.

Interactions & Warnings

People who have had a serious allergic reaction to basiliximab should not receive it. Tell the team if you have ever had basiliximab before, for example with an earlier transplant. The risk of a severe reaction on a second course is higher, especially if anti-rejection treatment was stopped early the first time because the transplant did not go ahead or the kidney was lost soon after. Any regimen that suppresses the immune system raises the risk of infections and, over the long run, some cancers such as lymphoma. In trials, adding basiliximab did not raise these risks compared with placebo, although serious cytomegalovirus (CMV, a common virus that can cause illness after transplant) infection was more frequent in people who were also taking a third anti-rejection drug. Report fever, chills, sore throat, or painful or reduced urination to the transplant team promptly. Check with the team before any vaccine, since it is not known how well vaccines work during treatment. Antibody medicines like basiliximab can cross the placenta, and its effect on a developing baby is unknown. People who could become pregnant should use effective birth control before treatment, during it and for 4 months after the last dose. It is not known whether it passes into breast milk, so breastfeeding needs a discussion with the team. No dose changes are needed when it is combined with the usual anti-rejection medicines.

What to Expect

For most people, basiliximab is a brief part of the transplant hospital stay rather than something they notice as a separate treatment. Its job is to lower the chance of an early rejection episode. In the main trials, about 30 to 33% of people who received it had a biopsy-confirmed rejection episode in the first six months, compared with 44 to 46% of those given placebo. It did not change one-year kidney or patient survival in those trials, but a large review of many studies found fewer kidneys lost in the first year. Basiliximab is one of several induction options. A stronger alternative, antithymocyte globulin (ATG), may prevent slightly more biopsy-proven rejection but causes more infusion reactions, more CMV disease and more cancers. The choice depends on the person's medical history and the transplant center's approach. After the two doses, follow-up focuses on the long-term anti-rejection medicines, regular blood tests of kidney function and drug levels, and watching for infection.

Questions to Ask Your Doctor

  1. 1.Why is basiliximab the induction treatment you recommend for me rather than antithymocyte globulin or no induction?
  2. 2.I have received basiliximab before. How does that change the risk of an allergic reaction, and what precautions will you take?
  3. 3.Which anti-rejection medicines will I take long term, and how will you monitor them after the two doses?
  4. 4.Which infections should I watch for in the first months after transplant, and who do I call if I get a fever?
  5. 5.If I might want to become pregnant or breastfeed, how should we plan around basiliximab and my other transplant medicines?

Last reviewed • Oct 2026

Educational content, not medical advice.